1. OC-005 A Multicenter, Double-Blind, Placebo (PBO)-Controlled Ph3 Study of Ustekinumab (UST), A Human IL-12/23P40 MAB, in Moderate-Severe Crohn's Disease (CD) Refractory to anti-TNFΑ: UNITI-1. (17th August 2016) Authors: Rutgeerts, P; Gasink, C; Blank, M; Lang, Y; Johanns, J; Gao, L-L; Sands, B; Hanauer, S; Feagan, B; Targan, S; Ghosh, S; de Villiers, W; Colombel, J-F; Lee, SD; Desreumaux, P; Loftus, EV; Vermeire, S; Sandborn, WJ Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PWE-047 Improved patient-reported outcomes with upadacitinib over 52 weeks in patients with moderate-to-severe crohn's disease. (June 2019) Authors: Peyrin-Biroulet, L; Louis, E; Loftus, EV; Lee, WJ; Cataldi, F; Lacerda, A; Ghosh, S Journal: Gut Issue: Volume 68(2019)Supplement 2 Page Start: A195 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗